Cas:366814-43-9 Pulsatilloside E manufacturer & supplier

Chemical Name:Pulsatilloside E

CAS.NO:366814-43-9

Synonyms:6-Deoxy-α-L-mannopyranosyl-(1->4)-β-D-glucopyranosyl-(1->6)-1-O-[(3β)-3-{[6-deoxy-α-L-mannopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->4)]-α-L-arabinopyranosyl]oxy}-23-hydroxy-28-oxo lup-20(29)-en-28-yl]-β-D-glucopyranose;β-D-Glucopyranose, O-6-deoxy-α-L-mannopyranosyl-(1->4)-O-β-D-glucopyranosyl-(1->6)-1-O-[(3β)-3-[[O-6-deoxy-α-L-mannopyranosyl-(1->2)-O-[β-D-glucopyranosyl-(1->4)]-α-L-arabinopy
 ranosyl]oxy]-23-hydroxy-28-oxolup-20(29)-en-28-yl]-;Pulsatilla saponin E

Molecular Formula:C₆₅H₁₀₆O₃₁

Molecular Weight:1383.519

HS Code:

Physical and Chemical Properties:

Melting point:205-208 ºC

Boiling point:N/A

Density:1.53±0.1 g/cm3

Index of Refraction:1.645

PSA:

Exact Mass:1382.671753

LogP:2.15

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-Deoxy-α-L-mannopyranosyl-(1-&gt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pulsatilla saponin E physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ranosyl]oxy]-23-hydroxy-28-oxolup-20(29)-en-28-yl]- Use and application,6-Deoxy-α-L-mannopyranosyl-(1-&gt technical grade,usp/ep/jp grade.

Related News: More than 50% of patients with SLE develop permanent organ damage, caused by the disease or existing treatments, which exacerbates symptoms and increases the risk of mortality. 2,5-Pyridinedicarboxamide,N5-[[[(3S)-1-[[3-(dimethylamino)-1,2,4-oxadiazol-5-yl]methyl]hexahydro-2-oxo-1H-azepin-3-yl]amino][(2-methyl-5-benzofuranyl)amino]methylene]-N2,N2-dimethyl- manufacturers During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031. 4-[4-Ethyl-3,5-bis-(4-methoxy-phenyl)-furan-2-yl]-phenol suppliers The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. rel-N-(((2R,5S)-5-(4-fluorophenyl)-1-tosylpyrrolidin-2-yl)methyl)pivalamide vendor & factory.